Search results
Results from the Health.Zone Content Network
On 28 May 2021, the Janssen vaccine was the fourth vaccine to be approved in the UK. On 3 February 2022, the Novavax vaccine was the fifth vaccine to be approved in the UK. On 14 April 2022, the UK became the first country to approve the Valneva vaccine. This is the sixth COVID-19 vaccine that the MHRA has approved. Rollout timeline
A vaccination schedule is a series of vaccinations, including the timing of all doses, which may be either recommended or compulsory, depending on the country of residence. A vaccine is an antigenic preparation used to produce active immunity to a disease , in order to prevent or reduce the effects of infection by any natural or "wild" pathogen ...
Immunisation against infectious disease is popularly known as The Green Book, to provide information on the UK's vaccination schedule and vaccines for vaccine preventable infectious diseases. [1] [2] It is a guide for health professionals and health departments that give vaccines in the UK. [2] Updates are added by its clinical editors through ...
A 2022 study of the Pfizer vaccine and the Omicron variant found that vaccine effectiveness was 67.2 percent in the 2 to 4 weeks after a booster, but declined to 45.7 percent after 10 or more weeks.
Staying up to date on vaccinations is important at every age, not just childhood. Vaccine recommendations for adults vary by age range, including under age 50, ages 50 to 65, and over the age of 65.
The bivalent vaccine used in the UK targets the BA.1 Omicron variant, while US vaccines target the BA.4 and BA.5 Omicron variants. These variants are all related to the currently circulating ...
The Joint Committee on Vaccination and Immunisation ( JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland ...
e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [33] [34] [35] using as a vector the modified chimpanzee ...